Daewoong and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery – QNT Press Release


CHENGDU, China, Nov. 13, 2022 /PRNewswire/ — Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”, SSE:688222.SH) today announced that it has entered into a research collaboration agreement with DAEWOONG PHARMACEUTICAL Co., Ltd (“Daewoong”), a global healthcare group in the Republic of Korea, dedicated to improving the quality of patients’ lives. HitGen will apply its DNA-encoded library (DEL) technology platform centered around the design, synthesis and screening of thousands of DELs that collectively comprise over 1.2 trillion small , drug-like molecules to discover compounds that bind to certain targets that Daewoong needs to discover for new drug development.

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center